sorafenib has been researched along with nsc 106399 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (nsc 106399) | Trials (nsc 106399) | Recent Studies (post-2010) (nsc 106399) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 82 | 0 | 57 |
| Protein | Taxonomy | sorafenib (IC50) | nsc 106399 (IC50) |
|---|---|---|---|
| Integrin alpha-L | Homo sapiens (human) | 0.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Türköz, Y; Üremiş, MM; Üremiş, N | 1 |
1 other study(ies) available for sorafenib and nsc 106399
| Article | Year |
|---|---|
Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triterpenes | 2023 |